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Abstract
Background: Preeclampsia is a debilitating disorder affecting approximately 3% of pregnant women in the Western 
world. Although inconclusive, current evidence suggests that the renin-angiotensin system may be involved in 
hypertension. Therefore, our objective was to determine whether the genes for placental renin (REN) and maternal 
angiotensinogen (AGT) interact to influence the risk of preeclampsia.
Methods: Three haplotype-tagging SNPs (htSNPs) covering REN (rs5705, rs1464818, and rs3795575) and another three 
covering AGT (rs2148582, rs2478545 and rs943580) were genotyped in 99 mother-father-child triads of preeclampsia 
pregnancies. We estimated relative risks (RR) conferred by maternal AGT and fetal REN haplotypes using HAPLIN, a 
statistical software designed to detect multi-marker transmission distortion among triads. To assess a combined effect 
of maternal AGT and fetal REN haplotypes, the preeclamptic triads were first stratified by presence/absence of maternal 
AGT haplotype C-T-A and tested for an effect of fetal REN across these strata.
Results: We found evidence that mothers carrying the most frequent AGT haplotype, C-T-A, had a reduced risk of 
preeclampsia (RR of 0.4, 95% CI = 0.2-0.8 for heterozygotes and 0.6, 95% CI = 0.2-1.5 for homozygotes). Mothers 
homozygous for AGT haplotypes t-c-g and C-c-g appeared to have a higher risk, but only the former was statistically 
significant. We found only weak evidence of an overall effect of fetal REN haplotypes and no support for our hypothesis 
that an effect of REN depended on whether the mother carried the C-T-A haplotype of AGT (p = 0.33).
Conclusion: Our findings indicate that the mother's AGT haplotypes affect her risk for developing preeclampsia. 
However, this risk is not influenced by fetal REN haplotypes.
Background
Preeclampsia is a heritable, complex and serious disorder
affecting approximately 3% of pregnant women in West-
ern populations [1]. The underlying disease mechanisms
are still unclear, but placental factors have been suggested
to operate via the maternal circulation in causing
endothelial dysfunction [2]. Maternal symptoms include
hypertension and proteinuria. Early in a preeclamptic
pregnancy, the spiral arteries are abnormally remodeled,
leading to deficient placental perfusion. For preeclampsia
to occur, however, reduced placental perfusion may have
to interact with maternal factors [3].
Recent epidemiological studies have demonstrated that
the risk of preeclampsia is determined not only by mater-
nal predisposition, but also by a fetal contribution inher-
ited from the father. Pregnant women whose partner had
fathered a preeclamptic pregnancy with another woman
were nearly twice as likely to have preeclampsia [4]. In
studies of the risk of preeclampsia across generations,
partners of men who were born to a preeclamptic preg-
nancy also had increased risk of developing preeclampsia
[5,6]. Despite evidence for both maternal and fetal
genetic contributions to the risk of preeclampsia, most
published reports are based on the case-control design
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that does not distinguish between maternal and fetal
gene-effects. Moreover, most of these studies have
focused entirely on maternal susceptibility genes [7,8].
Preeclampsia could be associated with a specific com-
bination of maternal and fetal alleles of the same or possi-
bly different genes. Indeed, there are several examples of
maternal-fetal gene-gene interactions in the literature.
For example, placental factors (determined by fetal genes)
have been suggested to raise maternal blood pressure,
whereas maternal factors (determined by maternal genes)
may counteract this rise in blood pressure [9]. Blood
pressure is regulated by the renin-angiotensinogen sys-
tem (RAS) through a cascade of AGT cleavage, generat-
ing the physiologically active angiotensin II. REN
catalyzes the rate-limiting step of this cascade, the con-
version of angiotensinogen to angiotensin I, and thus
determines the activity of the system [10]. It is not
known, however, whether the RAS system is involved in
the basic etiology of preeclampsia or simply in regulating
the maternal response to the condition.
An interaction of fetal REN  with maternal AGT  has
been demonstrated in animal models. When transgenic
female mice expressing human AGT  were mated with
transgenic males expressing human REN, the pregnant
females displayed a transient elevation of blood pressure
in late pregnancy due to secretion of placental human
REN  into the maternal circulation [11]. Similar results
were obtained from experiments in a transgenic rat
model of preeclampsia [12].
Given the strong link between REN and AGT, we aimed
to assess whether there is a combined effect of feto-pla-
cental REN and maternal AGT on risk of preeclampsia in
humans. We selected haplotype-tagging SNPs (htSNPs)
covering each of the two genes and explored their com-
bined association with preeclampsia in a clinically well-
described set of Norwegian family triads from preec-
lamptic pregnancies. We estimated the effects of mater-
nal  AGT  haplotypes, fetal REN  haplotypes, and the




From January 1993 to December 1995, umbilical cord
blood was collected from 8615 neonates delivered at the
Stavanger University Hospital in Norway as part of a
larger prospective study on risk factors associated with
sudden infant death syndrome (SIDS). Women who ful-
filled the diagnostic criteria for preeclampsia (n = 129),
their partner and their affected child were invited to par-
ticipate in the study [13]. Of these, one-hundred and two
family triads were recruited in the study. Mothers and
fathers donated peripheral blood post partum and gave
wri t t e n  i n f o r m ed  c o n s e n t  o n  be h a l f  o f  t h e m s e l v e s  a n d
their child. The study was approved by the Regional
Committee for Ethics and the Norwegian Data Inspec-
torate.
Genetic analysis
Genotype data from a 40 kb-long region covering REN
(GeneID: 5972) and AGT  (GeneID: 183), respectively,
were downloaded from the genome browser of the Inter-
national HapMap Consortium http://www.hapmap.org
and imported into Haploview 3.0 [14] for computation of
linkage disequilibrium (LD) statistics, identification and
evaluation of htSNPs. Only SNPs with minor allele fre-
quencies > 0.1 and haplotype blocks in LD with r2 > 0.8
were imported. NCBI assembly 34 of the human genome
and data release 14 were used. The exact locations of the
htSNPs were determined using the BLAT utility at the
UCSC Genome Bioinformatics site http://
www.genome.ucsc.edu.
DNA was extracted from heparin blood using the
QIAmp Blood Mini Kit (Qiagen, GmbH, Hilden, Ger-
many). The selected htSNPs for REN [rs5705 (A/c; lower-
case denotes the minor allele and uppercase the major
allele), rs1464816 (G/t), rs3795575 (C/t)) and AGT
(rs2148582 (C/t), rs2478545 (c/T), rs943580 (A/g)] were
genotyped by the SNaPshot ddNTP primer extension
method (Applied Biosystems, CA, USA). PCR primers
and SNP extension primers were synthesized by MWG
Biotech http://www.the-mwg.com and are listed in Table
1. Threeplex PCR reactions were performed for each
patient as follows: three pairs of PCR primers were ampli-
fied simultaneously in 12 μl reactions containing 10 mM
Tris HCl, pH 8.3, 50 mM KCl, 2.5 mM MgCl2, 0.2 mM
deoxynucleotide triphosphates, 1 M betain, 0.05 U/μl
AmpliTaq Gold DNA polymerase (Applied Biosystems)
and 0.1 μg DNA. For each htSNP, forward and reverse
primers were added to a final concentration of 0.2 μM,
except for the rs3795575 primers that were added to a
final concentration of 0.5 μM. REN threeplex amplifica-
tions were initiated by activation of the DNA polymerase
for 9 min at 95°C, followed by 26 cycles of denaturation at
95°C for 30 sec, annealing at 60°C for 30 sec and polymer-
ization at 72°C for 45 sec in a Master cycler XP (Eppen-
dorf AG, Hamburg, Germany). For the AGT  threeplex
reactions, forward and reverse primers were added to a
concentration of 0.5 μM, amplifications were performed
without betain, and annealing was conducted at 58°C.
The resulting PCR products (5 μl) were cleaned with
EXOSAP-IT (2 μl) (Amersham Biosciences AB, Uppsala,
Sweden) following the SNaPshot reaction.
SNP extension primers were designed to target DNA
sequences next to their polymorphic sites, with a 5'-tail
differing in lengths of 20 to 39 nucleotides (Table 1). The
single-base extension reaction (10 μl) contained 3 μl of
SNaPshot Multiplex kit (Applied Biosystems), 1 μMVefring et al. BMC Medical Genetics 2010, 11:90
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pooled SNP extension primers and 0.5 μl REN or AGT
threeplex PCR product. Samples were amplified for 25
cycles with 10 sec of denaturation at 96°C, 5 sec of
annealing at 50°C and 30 sec of polymerization at 60°C.
The reaction products were treated with Shrimp Alkaline
Phosphatase (Amersham Biosciences) for 60 min at 30°C
followed by 30 min at 75°C. The resulting AGT or REN
threeplex SNaPshot products (0.5 μl) were added to 20 μl
of Hi-Di™ Formamide containing 0.2% Liz 120 size stan-
dard (Applied Biosystems) and loaded on an ABI PRISM®
310 instrument (Applied Biosystems) to separate the
products. Genotyping was performed in duplicate. For
genotype determination, the results were analyzed using
the GeneMapper software, v3.0 (Applied Biosystems).
Genotypes of the REN and the AGT htSNP were validated
by direct cycle sequencing of 10 randomly selected family
triads.
Statistical analysis
One important purpose of this study was to demonstrate
an approach for studying maternal-fetal gene-gene inter-
actions. We used the HAPLIN statistical software pack-
age http://www.uib.no/smis/gjessing/genetics/software/
haplin; [15]) to reconstruct haplotypes from htSNP geno-
type data and to estimate the relative risk associated with
a single or double dose of each haplotype among the
mother-father-child triads. An attractive feature of HAP-
LIN is that relative risk estimates for maternal and fetal
alleles/haplotypes are unconfounded. Since our purpose
was to estimate the joint effect of maternal AGT haplo-
types and fetal REN haplotypes, we first identified mater-
nal AGT haplotypes that could be associated with risk.
Next, we stratified the preeclampsia triads by presence/
absence of these maternal AGT  risk-haplotypes to see
whether the effect of fetal REN haplotypes differed signif-
icantly across strata of maternal AGT haplotype. A likeli-
hood-based test was performed to test for such a
difference.
Results
One-hundred and two mother-father-child triads of
preeclamptic pregnancies were genotyped for three
Table 1: PCR primers and SNP extension primers




SNP-F: AGTGGAGCCAACCCATGAAGAGGCTGAC 29 bp
rs1464816 REN-F: TCCTTGGTTGGAGTCTGGTC
REN-R: GCTTTTCTTTTGCTGCTTGG
SNP-F: AAAAACACAGAGTGTGTGCGTGCAGGGTTGAGG 34 bp
rs3795575 REN-F: AAGAAGCCAAAGAGGGAAGG
REN-R: GAAAGAGATGTCGGGGAGTG




SNP-F: AGGAGTATAAAGTTGCCAAC 21 bp
rs2148582 AGT-F: CTGCCGTTGTTCTGGGTACT
AGT-R: CACAAGCCCTGCTATTCCTC
SNP-F: AAAAAAGTTACATCTGAGAGAGACAAG 28 bp
rs2478545 AGT-F: ACCACGACAACCTCCTTGAG
AGT-R: GACCCATTTCAGATGCCACT
SNP-F: AAAAAAAAAAGCCTGCTGTCCCTAGGAGAAGTG 34 bpVefring et al. BMC Medical Genetics 2010, 11:90
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htSNPs covering REN  [rs5705 (A/c), rs1464816 (G/t),
rs3795575 (C/t); Figure 1A] and three additional htSNPs
covering  AGT  [rs2148582 (C/t), rs2478545 (c/T),
rs943580 (A/g); Figure 1B]. Three family triads were
excluded from the analyses because of inconsistent geno-
types between the mother, father and child. Duplicate
analysis of the AGT and REN threeplex reactions was per-
formed on the remaining 99 family triads; no inconsisten-
c i e s  i n  g e n o t y p e  w e r e  o b s e r v e d .  F u r t h e r ,  n o n e  o f  t h e
htSNPs showed any statistically significant deviation
from Hardy-Weinberg equilibrium.
REN and AGT haplotypes
With three diallelic htSNPs, there are eight possible hap-
lotypes for each gene. We estimated, separately, the
effects of carrying one and two copies of REN haplotypes
among mothers and their offspring (a total of four sets of
analyses). This was repeated for maternal and fetal AGT
haplotypes. Haplotype frequencies, RR estimates with
95% confidence intervals (CI) and the corresponding p-
values are presented in Tables 2 and 3. REN and AGT
h a p l o t y p e s  w i t h  a  f r e q u e n c y  o f  l e s s  t h a n  5 %  w e r e
excluded from the analyses because of the difficulty in
obtaining valid RR estimates for rare haplotypes. Among
AGT haplotypes, C-T-A was the most common (58.3%),
while C-c-g and c-G-t had frequencies of 20.9% and
20.4%, respectively (Table A2A). Among REN haplotypes,
A-G-C was the most prevalent (59.5%), followed by A-t-C
and c-G-t, with frequencies of 31.6% and 8.5%, respec-
tively (Table B2B).
Maternal effects
There was a significant protective effect (RR = 0.4; 95%
CI = 0.2-0.8; p = 0.02) among mothers heterozygous for
the most frequent AGT haplotype, C-T-A (Table A2A).
Among mothers homozygous for C-T-A, however, the
protective effect was weaker and did not reach statistical
significance (RR = 0.6; 95% CI = 0.2-1.5). Still, the esti-
mated effects are in the same direction and indicate that
presence of the C-T-A haplotype may be protective. As a
result, we assumed a dominant effect for C-T-A in subse-
quent analyses. A risk of preeclampsia was also seen
among mothers carrying the other two AGT haplotypes.
Notably, mothers homozygous for the AGT haplotypes t-
c-g and C-c-g had a RR of 4.6 (95% CI = 1.5-14.7, p = 0.01)
and 3.0 (95% CI = 0.9-9.9, p = 0.07), respectively, with
only the former being nominally significant. For
heterozygous carriers of the same two AGT haplotypes,
the corresponding RR estimates were 1.5 (95% CI = 0.7-
3.2, p = 0.35) for t-c-g and 1.4 (95% CI = 0.7-3.1, p = 0.38)
for C-c-g. Overall, the mother's REN haplotypes did not
affect her risk of developing preeclampsia (data not
shown).
Fetal effects
Our data showed evidence of a protective effect on the
risk of preeclampsia among children who were homozy-
Figure 1 Example of a typical REN (A) and AGT (B) threeplex reaction A. The SNaPshot result of a homozygous carrier of the most common REN 
haplotype, A-G-C (SNP order: rs5705, rs1464816 and rs3795575). B. The SNaPshot result of a patient carrying both the AGT haplotype C-T-A and hap-




rs5705 (A/A) rs943580 (T/c = A/g)
rs2478545 (c/T)
rs2148582 (G/a = C/t) Vefring et al. BMC Medical Genetics 2010, 11:90
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gous for the REN haplotype A-G-C (RR = 0.4; 95% CI =
0.1-1.0; p = 0.05) (Table B2B). In contrast, the child's REN
haplotypes A-t-C and c-G-t did not affect the mother's
risk of preeclampsia, and neither did the child's AGT hap-
lotypes C-T-A, C-c-g or t-c-g (data not shown).
REN and AGT interaction
To assess interaction between REN and AGT haplotypes,
we fitted models with fetal REN haplotype effects into
strata of families defined by maternal AGT  haplotypes.
One stratum consisted of mothers carrying the appar-
ently protective C-T-A haplotype (57 family triads) (Table
A3A), while the other stratum consisted of mothers who
did not carry the C-T-A haplotype (27 family triads)
Table 2: Relative risk estimates for REN (A) and AGT (B) haplotypes
A: Relative risk estimates (95% CI; p-value) for maternal AGT haplotypes (n = 87 family triads)
AGT haplotype Frequency (%) Single dose Double dose
C-T-A 58.3 0.39 (0.18-0.84); 0.02 0.60 (0.24-1.51); 0.28
C-c-g 20.9 1.42 (0.65-3.12); 0.38 3.00 (0.93-9.93); 0.07
t-c-g 20.4 1.46 (0.66-3.20); 0.35 4.63 (1.46-14.7); 0.01
B: Relative risk estimates (95% CI; p-value) for fetal REN haplotypes (n = 90 family triads)
REN haplotype Frequency (%) Single dose Double dose
A-G-C 59.5 0.63 (0.27-1.46); 0.27 0.36 (0.13-0.98); 0.05
A-t-C 31.6 0.86 (0.37-1.95); 0.72 0.40 (0.12-1.39); 0.15
c-G-t 8.5 1.45 (0.66-3.19); 0.35 Not estimable
SNP order for AGT: rs218582 (C/t), rs2478545 (c/T) and rs943580 (A/g)
SNP order for REN: rs5705 (A/c), rs1464816 (G/t) and rs3795575 (C/t)
Table 3: Relative risk estimates for REN and AGT interactions:
A: Relative risk estimates (95% CI; p-value) for fetal REN haplotypes when mothers carry the protective AGT haplotype C-T-A (n = 57 
family-triads)
REN haplotype Frequency (%) Single dose Double dose
A-G-C 61.3 0.62 (0.22-1.71); 0.36 0.33 (0.09-1.19); 0.09
A-t-C 29.4 1.03 (0.38-2.82); 0.96 0.62 (0.14-2.79); 0.54
c-G-t 8.9 1.29 (0.50-3.25); 0.59 Not estimable
B: Relative risk estimates (95% CI; p-value) for fetal REN haplotypes when mothers do not carry the protective AGT haplotype C-T-A 
(n = 27 family-triads)
REN haplotype Frequency (%) Single dose Double dose
A-G-C 55.2 1.53 (0.16-14.90); 0.71 1.0 (0.08-12.4); 0.99
A-t-C 38.0 2.40 (0.24-24.10); 0.46 0.89 (0.06-15.20); 0.93
c-G-t 5.8 0.60 (0.09-4.14); 0.60 Not estimable
SNP order for REN: rs5705 (A/c), rs1464816 (G/t) and rs3795575 (C/t)Vefring et al. BMC Medical Genetics 2010, 11:90
http://www.biomedcentral.com/1471-2350/11/90
Page 6 of 7
(Table B3B). There was little evidence of an effect of REN
in either of these strata. When we compared this strati-
fied model with an overall model using a likelihood-based
test, there was no evidence that fetal REN had a different
effect based on presence/absence of the maternal AGT
haplotype C-T-A (p = 0.33). We did not test for interac-
tion between fetal AGT  haplotypes and maternal REN
haplotypes, as it was deemed implausible.
Discussion
We found a significant association between maternal
AGT  haplotypes and preeclampsia in our data. This is
consistent with the results of a previous case-control
study of French-Canadian Caucasians, where preeclamp-
tic women carrying the AGT  A-Met-Thr (G1035A-
Thr174Met-Met235Thr) haplotype had a 2.1 fold (p =
0.0008) increased risk of disease compared to control
subjects [16]. In contrast, a larger British study - also
known as the Genetics of Preeclampsia Consortium
(GOPEC) - failed to replicate an association of maternal
AGT  haplotype with preeclampsia after analyzing 398
maternal (grandmother-grandfather-mother) triads and
536 fetal (mother-father-child) triads [17].
Except for a borderline-significant double-dose effect
of one of the haplotypes, fetal REN haplotypes did not
appear to influence the mother's risk of preeclampsia. A
large-scale genetic association study of 394 preeclamptic
women and their 324 offspring from Chile [18] found no
evidence of association between fetal REN variants and
preeclampsia.
Our hypothesis and analyses were based on findings
from a previous mouse-model study in which strong evi-
dence of a gene-gene interaction between AGT and REN
was found [11]. Specifically, preeclampsia-like symptoms
were observed when females carrying human AGT were
mated with males carrying human REN, whereas preg-
nant mice derived from other mating combinations did
not manifest preeclamptic symptoms. This suggests that
human REN produced by the paternal gene in the pla-
centa may enter the maternal circulation and interact
with maternal AGT to increase the expression of symp-
toms of preeclampsia [11]. Similar results have been
obtained from experiments in rats [12]. Since there is no
evidence that the REN gene is imprinted, we did not dif-
ferentiate between paternally-inherited REN and mater-
nally-inherited REN when estimating the effects of fetal
REN. There was no evidence of interaction between
maternal AGT and fetal REN among our 99 preeclamptic
mother-father-child triads.
Given our limited sample size, we decided not to test all
possible combinations of maternal AGT  and fetal REN
haplotypes. One hundred triads should give adequate
power (80%) to detect a relative risk of 2.5 or higher con-
ferred by either a maternal or a fetal allele [19,20]. Our
study is under-powered to detect moderate gene-gene
interaction effects; thus, we cannot rule out such interac-
tions. There is, however, little evidence of strong interac-
tions in our data.
Although REN is an attractive candidate gene for preec-
lampsia, only a few studies have investigated associations
of REN with preeclampsia. For example, REN did not fea-
ture in GOPEC's list of candidate genes [17]; only AGT,
angiotensin II receptor 1 (AGTR1), coagulation factor V
(F5) and II (F2), methylene tetrahydropholate reductase
(MTHFR), endothelial nitric oxide synthase (NOS3) and
tumor necrosis factor alpha (TNF) were investigated.
Despite recent reports supporting the hypothesis that
both maternal and fetal genes may be involved in the
development of preeclampsia, only a few studies have
investigated fetal genetic contributions, and even fewer
have used a study design that can distinguish between
maternal and fetal gene-effects. Identification of joint
maternal and fetal risk factors for preeclampsia is impor-
tant for better defining risk and risk outcomes.
In conclusion, we examined the possibility of an inter-
action between maternal AGT and fetal REN haplotypes
by applying new statistical methodologies that can esti-
mate these effects without confounding in a family-triad
setting. We found an association between maternal AGT
haplotypes and preeclampsia, and a weak association
between fetal REN and preeclampsia. There was, how-
ever, no interaction between maternal AGT and fetal REN
haplotypes. The mother-father-child triad approach is
recommended in future genetic studies of preeclamptic
risk factors since this design enables the separate estima-
tion of maternal and fetal gene-effects as well as interac-
tion of maternal and fetal genes.
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